Cholesterol-lowering effect of ezetimibe in uridine diphosphate glucuronosyltransferase 1A-deficient (Gunn) rats

Drug Metabolism and Disposition

Volumn 35, Issue 9, 2007, Pages 1455-1458

  Yamamoto, Takehito ^a   Ito, Kousei ^a   Honma, Masashi ^a   Takada, Tappei ^a   Suzuki, Hiroshi ^a  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; DRUG METABOLITE; EZETIMIBE; EZETIMIBE GLUCURONIDE; GLUCURONIDE; GLUCURONOSYLTRANSFERASE 1A1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BILIARY EXCRETION; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EXCRETION; DRUG GLUCURONIDATION; DRUG METABOLISM; ENZYME DEFICIENCY; HEREDITY; IN VITRO STUDY; IN VIVO STUDY; INTESTINE; LIVER MICROSOME; MALE; MICROSOME; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STRAIN DIFFERENCE; WISTAR RAT;

ANIMALS; ANTICHOLESTEREMIC AGENTS; AZETIDINES; BILE; BLOOD PROTEINS; CHOLESTEROL; GLUCURONOSYLTRANSFERASE; INTESTINAL ABSORPTION; INTESTINAL MUCOSA; MALE; MICROSOMES, LIVER; RATS; RATS, GUNN; RATS, WISTAR;

RATTUS; RATTUS NORVEGICUS;

EID: 34548080154     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.015628     Document Type: Article

References (18)

1. Altmann SW, Davis HR Jr, Zhu LJ, Yao X, Hoos LM, Tetzloff G, Iyer SP, Maguire M, Golovko A, Zeng M, et al. (2004) Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 303:1201-1204.
2. Fasco MJ, Silkworth JB, Dunbar DA, and Kaminsky LS (1993) Rat small intestinal cytochromes P450 probed by warfarin metabolism. Mol Pharmacol 43:226-233.
3. Garcia-Calvo M, Lisnock J, Bull HG, Hawes BE, Burnett DA, Braun MP, Crona JH, Davis HR Jr, Dean DC, Detmers PA, et al. (2005) The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci 102:8132-8137.
4. Ghosal A, Hapangama N, Yuan Y, Achanfuo-Yeboah J, Iannucci R, Chowdhury S, Alton K, Patrick JE, and Zbaida S (2004) Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of ezetimibe (Zetia). Drug Metab Dispos 32:314-320.
5. Hawes BE, O'Neill KA, Yao X, Crona JH, Davis HR, Graziano MP, and Altmann SW (2007) In vivo reponsiveness to ezetimibe correlates with Niemann-Pick C1 like-1 (NPC1L1) binding affinity: comparison of multiple species NPC1L1 orthologs. Mol Pharmacol 71:19-29.
6. Hawk CT and Leary SL (1995) in Formulary for Laboratory Animals, p 74, Iowa State University Press, Ames, IA.
7. Higuchi K, Kobayashi Y, Kuroda M, Tanaka Y, Itani T, Araki J, Mifuji R, Kaito M, and Adachi Y (2004) Modulation of organic anion transporting polypeptide 1 and multidrug resistance protein 3 expression in the liver and kidney of Gunn rats. Hepatol Res 29:60-66.
8. Iyanagi T (1991) Molecular basis of multiple UDP-glucuronosyltransferase isoenzyme deficiencies in the hyperbilirubinemic rat (Gunn rat). J Biol Chem 266:24048-24052.
9. Kosoglou T, Statkevich P, Johnson-Levonas AO, Paolini JF, Bergman AJ, and Alton KB (2005) Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet 44:467-494.
10. Omura T and Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239:2370-2378.
11. Oswald S, Haenisch S, Fricke C, Sudhop T, Remmler C, Giessmann T, Jedlitschky G, Adam U, Dazert E, Warzok R, et al. (2006a) Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphate-glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans. Clin Pharmacol Ther 79:206-217.
12. Oswald S, Scheuch E, Cascorbi I, and Siegmund W (2006b) A LC-MS/MS method to quantify the novel cholesterol lowering drug ezetimibe in human serum, urine and feces in healthy subjects genotyped for SLCO1B1. J Chromatogr B Analyt Technol Biomed Life Sci 830:143-150.
13. Oswald S, Westrup S, Grube M, Kroemer HK, Weitschies W, and Siegmund W (2006c) Disposition and sterol-lowering effect of ezetimibe in multidrug resistance-associated protein 2-deficient rats. J Pharmacol Exp Ther 318:1293-1299.
14. Patrick JE, Kosoglou T, Stauber KL, Alton KB, Maxwell SE, Zhu Y, Statkevich P, Iannucci R, Chowdhury S, Affrime M, et al. (2002) Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects. Drug Metab Dispos 30:430-437.
15. Tso P, Balint JA, and Rodgers JB (1980) Effect of hydrophobic surfactant (Pluronic L-81) on lymphatic lipid transport in the rat. Am J Physiol 239:G348-G353.
16. van Heek M, Farley C, Compton DS, Hoos L, Alton KB, Sybertz EJ, and Davis HR Jr (2000) Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br J Pharmacol 129:1748-1754.
17. Yamanashi Y, Takada T, and Suzuki H (2007) Niemann-Pick C1-like 1 overexpression facilitates ezetimibe-sensitive cholesterol and beta-sitosterol uptake in CaCo-2 cells. J Pharmacol Exp Ther 320:559-564.
18. Zaks A and Dodds DR (1998) Enzymatic glucuronidation of a novel cholesterol absorption inhibitor, Sch 58235. Appl Biochem Biotechnol 73:205-214.